Top Stories
Partner Eli Lilly plans to participate in the offering.
Molecular gates are oral small molecules capable of eliminating difficult-to-drug proteins by selectively their progress through the secretory channel.
The transaction adds Aqneursa, which is approved for Niemann-Pick disease type C, and was recently cleared for ataxia-telangiectasia.
Vaxcyte's VAX-31 demonstrated non-inferiority to Pfizer's 20-valent pneumococcal vaccine Prevnar 20 and Merck & Co.'s 21-valent pneumococcal shot Capvaxive.
The partners will co-develop and co-promote lixudebart, with CSL funding trials across three indications.
Conference News
The Board of Directors (the ‘‘Board’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) is pleased to announce that the Group will present the late...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevib...
IRVINE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming American Society of Nephr...
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-i...
GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early DetectionGRAIL to Pr...
